Abstract
The study included patients with type 2 diabetes mellitus and impaired carbohydrate tolerance associated with arterial hypertension, patients with arterial hypertension, and healthy volunteers. We evaluated the levels of matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase type 1 (TIMP-1), glucose, insulin, C-peptide, glycated hemoglobin, and spontaneous and mitogen-activated cytokine secretion (IL-2, IL4, IL-6, IL-10, IL-17, TNF-α, and IFN-γ). Patients with type 2 diabetes mellitus in combination with arterial hypertension exhibited maximum TIMP-1 levels and TIMP-1/MMP-2, TIMP-1/ MMP-9 ratios as well as enhanced secretion of TNF-α, IL-6, IL-17 and reduced secretion of IL-10 in comparison with healthy individuals. The observed shifts are probably determined the development of systemic hyperinsulinemia in patients suffering from type 2 diabetes mellitus coupled with arterial hypertension.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Blood Glucose
-
Case-Control Studies
-
Cytokines / blood*
-
Cytokines / metabolism
-
Diabetes Complications / blood*
-
Diabetes Complications / enzymology
-
Diabetes Complications / etiology
-
Diabetes Mellitus, Type 2 / blood*
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / enzymology
-
Female
-
Glucose Intolerance / blood*
-
Glucose Intolerance / enzymology
-
Humans
-
Hypertension / blood*
-
Hypertension / enzymology
-
Hypertension / etiology
-
Male
-
Matrix Metalloproteinase 2 / blood
-
Matrix Metalloproteinase 2 / metabolism
-
Matrix Metalloproteinase 9 / blood
-
Matrix Metalloproteinase 9 / metabolism
-
Middle Aged
-
Tissue Inhibitor of Metalloproteinase-1 / blood
-
Tissue Inhibitor of Metalloproteinase-1 / metabolism
Substances
-
Blood Glucose
-
Cytokines
-
TIMP1 protein, human
-
Tissue Inhibitor of Metalloproteinase-1
-
MMP2 protein, human
-
Matrix Metalloproteinase 2
-
MMP9 protein, human
-
Matrix Metalloproteinase 9